π BEIJING, CHINA
13.11.2026 01:08 UTC
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug β Key Global Developments
Verified reporting indicates that eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug. Additional details from primary dispatches note: China has approved US pharmaceutical giant Eli Lill...